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Abstract
Background: The capacity of plants and plant cells to produce large amounts of recombinant protein has been well
established. Due to advantages in terms of speed and yield, attention has recently turned towards the use of transient
expression systems, including viral vectors, to produce proteins of pharmaceutical interest in plants. However, the effects of
such high level expression from viral vectors and concomitant effects on host cells may affect the quality of the
recombinant product.
Methodology/Principal Findings: To assess the quality of antibodies transiently expressed to high levels in plants, we have
expressed and characterised the human anti-HIV monoclonal antibody, 2G12, using both replicating and non-replicating
systems based on deleted versions of Cowpea mosaic virus (CPMV) RNA-2. The highest yield (approximately 100 mg/kg wet
weight leaf tissue) of affinity purified 2G12 was obtained when the non-replicating CPMV-HT system was used and the
antibody was retained in the endoplasmic reticulum (ER). Glycan analysis by mass-spectrometry showed that the
glycosylation pattern was determined exclusively by whether the antibody was retained in the ER and did not depend on
whether a replicating or non-replicating system was used. Characterisation of the binding and neutralisation properties of
all the purified 2G12 variants from plants showed that these were generally similar to those of the Chinese hamster ovary
(CHO) cell-produced 2G12.
Conclusions: Overall, the results demonstrate that replicating and non-replicating CPMV-based vectors are able to direct the
production of a recombinant IgG similar in activity to the CHO-produced control. Thus, a complex recombinant protein was
produced with no apparent effect on its biochemical properties using either high-level expression or viral replication. The
speed with which a recombinant pharmaceutical with excellent biochemical characteristics can be produced transiently in
plants makes CPMV-based expression vectors an attractive option for biopharmaceutical development and production.
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Introduction
Plant viruses have been used as vectors for the expression of
recombinant proteins for over 20 years. Recently, a number of
pharmaceutically relevant proteins have been produced using
vectors based on full-length plant virus genomes [1,2]. Though
such vectors have the advantage that they can spread systemically
within a plant and can be readily transmitted in order to bulk up
material, they suffer from disadvantages in terms of the size of
insert which can be stably incorporated and raise issues of
biocontainment. As a result, attention has turned towards the
development of deconstructed or deleted versions of plant virus-
based expression systems that can alleviate the disadvantages of
full-length viral vectors while retaining speed and high productiv-
ity. Deleted versions of the RNA viruses, Tobacco mosaic virus
(TMV), Potato virus X (PVX), and Cowpea mosaic virus (CPMV)
RNA-2 have successfully been used been used to produce a variety
of proteins in plants [3–6]. In these vectors the region encoding the
coat protein(s) was removed, limiting the ability of the virus to
spread within the plant but providing a substantial measure of
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13976biocontainment. High level expression is achieved by retaining the
ability of the viral RNA to be replicated by its cognate RNA-
dependent RNA polymerase and through the efficient delivery of
the constructs to cells by agro-infiltration.
A potential drawback of replicating virus-based expression
systems, which has to date received little attention, is that expression
of viral proteins [7], as well as the regulation of host proteome
associated with viral replication [8,9], causes substantial changes to
the host cells. For example, expression of the replication-related
proteins encoded by CPMV RNA-1 is known to induce a massive
proliferation of endoplasmic reticulum (ER)-derived membranes
[10–12]. Since the ER is essential for folding and post-translational
modification of glycoproteins such as antibodies, perturbations to
the endomembrane system could result in a reduction in quality of
recombinant protein or in different post-translational modification
patterns (includingN-glycosylation). On the other hand, an increase
in ER-derived membranes, as observed in differentiated plasma B-
cells, can have a beneficial effect by increasing capacity for the
accumulation of immunoglobulins. Furthermore, the high levels of
protein synthesis which can be achieved using viral vectors could
potentially affect the quality of the protein by, for example,
saturating certain host components necessary for quality control or
post-translational modification.
The properties of a recombinant pharmaceutical, such as an
antibody, are clearly crucial for its proper function and have,
therefore, been studied extensively in a number of production
systems. Recently, the broadly neutralising anti-Human immunode-
ficiency virus (HIV) human monoclonal antibody (mAb), 2G12
[13,14], has attracted considerable interest as a microbicide for
preventing the spread of HIV. This antibody recognizes a highly
conserved epitope consisting of high-mannose N-glycans on the
HIV-1 gp120 envelope protein [14] and has a potent and broad
HIV-1-neutralizing activity in vitro and in vivo [15]. Studies in
primates have demonstrated the ability of 2G12 to control
infection and prevent transmission when supplied parenterally
and through mucosal tissue [16–19]. Antibody cocktails including
2G12 have proven able to reduce the rate of viral rebound after
ending antiretroviral treatment in some human patients [20], but
the use of these cocktails requires multiple high doses. To assess
whether plants could serve as a source of large quantities of 2G12,
the full-size antibody has been expressed in transgenic Arabidop-
sis, tobacco and maize [21–23]. These reports rigorously and
indisputably demonstrated the potential and flexibility of recom-
binant antibody production afforded by expression in plants.
However, the use of transient expression systems, both viral and
non-viral, can deliver significant advantages for recombinant
protein production over transgenic plants in terms of yield and
speed of expression.
We have previously shown that replication-competent versions of
a deleted version of CPMV RNA-2 (delRNA-2)[24] can be used to
produce assembled IgG molecules in plants [25]. While the
delRNA-2 system relies on the simultaneous presence RNA-1 for
its replication, we have shown that very high levels of assembled
2G12 molecules can be produced using the non-replicating CPMV-
HT system, which does not require the presence of RNA-1 [26].
The present study reports the results of an investigation into the
biochemical properties and in vitro activity and neutralisation
capabilities of purified 2G12 produced by transient expression in
Nicotiana benthamiana using these replicating and non-replicating
systems. In particular, the effect of the ER remodelling caused by
RNA-1 on the quality of purified antibody was assessed. The results
show that neither the presence of RNA-1 nor high levels of transient
expression achieved with the CPMV-HT system have marked
effects onthe properties andefficacy of2G12 when compared to the
Chinese hamster ovary (CHO) cell-produced antibody. Thus, in
view of the speed advantage over transgenic plants, CPMV-based
transient expression vectors offer an attractive option for develop-
ment of plant-produced pharmaceuticals.
Results
Purification of
CPMV2G12 produced in plants by delRNA-2
plus RNA-1 or CPMV-HT
To examine the properties of 2G12 transiently expressed in N.
benthamiana using both replicating and non-replicating CPMV
vectors, two series of plasmids were used. These consisted of the
Heavy (H) chain, with and without a KDEL ER-retention sequence
at its C-terminus or Light (L) chain, inserted into either delRNA-2
or CPMV-HT (Figure 1). Agrobacterium suspensions containing the
various versions of the H chain were mixed with the L chain and
with equal amounts of an Agrobacterium suspension containing
plasmid pBIN61-P19, which expresses the suppressor of silencing
P19. For the delRNA-2 constructs an Agrobacterium suspension
containing plasmid pBinPS1NT, which is a full-length copy of
CPMV RNA-1, was also added. The mixtures were used to
agroinfiltrate all fully-expanded leaves of 6-week old N. benthamiana,
from which tissue was harvested at 6 days post-infiltration and the
IgG molecules purified by protein-A affinity chromatography. At
each step of the purification, the concentration of 2G12 was
monitored bysurface-plasmon resonance(SPR;Table1).Theyields
of IgG produced using CPMV-HT (
HT2G12HL and
HT2G12HEL)
were significantly higher (approximately 5-fold) than when
delRNA-2 was used in the presence of RNA-1 (
CPMV2G12HL
and
CPMV2G12HEL). With both systems, higher levels of antibody
were obtained when KDEL sequence was present.
Integrity of
CPMV2G12 and
HT2G12
The integrity of the purified 2G12 was assessed by SDS-PAGE
and Western blot analysis under reducing conditions with CHO-
produced 2G12 providing a protein standard (Figure 2). The
Coomassie blue-stained gel showed that the main products were
the H and L chains which co-migrated with the equivalent bands
from CHO-produced 2G12 (
CHO2G12). The plant-produced
material contained some additional protein bands, not present in
the CHO-produced material, which Western blot analysis using
anti-Fc and anti-Fab antibody identified as H chain-derived
degradation products. Furthermore, a doublet of ,110 kDa is
present in the material purified from plants, which probably
corresponds to cross-linked H chain dimers. Thus, the plant
derived 2G12 is not as pure as the
CHO2G12 due to the presence
of some product-related impurities. The presence of degradation
products after a single-step protein-A affinity purification has been
previously observed [22,27,28], and these contaminants can be
removed by additional purification steps. Importantly, this analysis
showed no significant differences between 2G12 produced by
delRNA-1 with RNA-1 or by CPMV-HT.
Glycan analysis of
CPMV2G12 and
HT2G12
The glycosylation of the plant-produced antibody preparations
was of particular interest due to the potential of the remodelling of
the endomembrane system by RNA-1 to affect protein maturation
and modification. Mass spectrometry was used to analyse the N-
linked glycan profiles of purified samples of both ER-retained
(2G12HEL) and secreted (2G12HL) forms expressed from
delRNA-2 in the presence of RNA-1 or by CPMV-HT in its
absence. As expected the ER-retained forms,
CPMV2G12HEL and
HT2G12HEL, displayed mostly oligo-mannosidic type glycans,
with Man-7 and Man-8 predominating, typical of KDEL-tagged
High-Yield Plant mAb Quality
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found (total ,2%), showing that KDEL-mediated ER retrieval of
2G12 is highly efficient. In contrast, the majority of glycan
structures on
CPMV2G12HL and
HT2G12HL were plant-specific
complex type residues typical of secretion in plant cells (Figure 3).
The major N-glycans GnGnXF and GnMXF accounted for
74.9% for
CPMV2G12HL and 67.8% for
HT2G12HL. Only a small
fraction of oligo-mannosidic type N-glycans (total ,16%) were
found, showing that exit from the ER was efficient for both
CPMV2G12HL and
HT2G12HL.
The observed glycan profiles for 2G12 expressed by both
delRNA-2 in the presence of RNA-1 and by CPMV-HT do not
differ significantly from each other. Furthermore, whether ER-
retained or secreted, the glycosylation patterns are similar to those
from 2G12 expressed in other systems [27](Sack M and Stadlmann
J, unpublished observations) and to other antibodies produced in
plants [29]. In the case of delRNA-2 with RNA-1, further
investigations showed that an in-plant incubation time of 12 days,
as opposed to the usual 6 days, revealed a positive effect of the
presence of RNA-1 on accumulation levels of ER-retained 2G12.
Although there was a shift in the predominance of a particular
glycotype over time, only minor differences in the N-linked glycan
profile were observed for 2G12 samples at 6 or 12 days between the
presence and absence of RNA-1 (Figure S1). Therefore, neither the
presence of RNA-1 nor the high-level accumulation from CPMV-
HT expression impacted greatly on 2G12 glycosylation.
Quality and activity analysis of
CPMV2G12 and
HT2G12 by
Surface Plasmon Resonance
The binding properties of purified delRNA-2 and CPMV-HT-
produced 2G12 were evaluated by SPR-based binding assays
using surfaces immobilized with protein-A, protein-L or HIV
gp120. Each immobilized ligand probes a specific binding region
on the antibody and the ratios of the measured response can be
used to compare and evaluate the quality of antibody prepara-
tions. Inactivation of a ligand binding site can result from absence
Table 1. Purification of
CPMV2G12 and
HT2G12 variants from infiltrated tissue.
2G12 variant Leaf mass (g) Extract volume (ml) 2G12 conc. (mg/ml) 2G12 yield (mg) % Recovery
mg recovered/kg of
fresh weight tissue
CPMV2G12HL 176.0 485 5.37 2.6 73% 10.8
HT2G12HL 134.9 435 20.57 9.0 79% 52.6
CPMV2G12HEL 105.9 315 12.75 4.0 71% 26.9
HT2G12HEL 85.6 290 36.56 10.6 85% 105.1
doi:10.1371/journal.pone.0013976.t001
Figure 1. Schematic representation of the plant expression cassettes used to express 2G12. White boxes represent CPMV coding
sequences, light and dark grey boxes represent 2G12 light and heavy chains respectively.
doi:10.1371/journal.pone.0013976.g001
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unexpected modification of the binding site, and will affect the
response ratios. The response ratios were directly derived by linear
regression of the endpoint signals measured for different
concentrations (Figure 4) and the relative response ratios are
reported in Table 2. The
CHO2G12 was again employed as a
reference standard. For the plant-produced material, the gp120/
protein-A ratio varied from 69 to 89% of the response ration of
CHO2G12 and the gp120/protein-L ratio was 74 to 90% of the
response ration of
CHO2G12. These results show that the plant-
Figure 2. Electrophoretic analysis of protein-A purified 2G12 variants produced by delRNA-2 + RNA-1 or with CPMV-HT. 12% SDS-
PAGE under reducing conditions was used to separate 4 mg of 2G12 preparations for Coomassie staining and 50 ng for immunological detection of
samples from
CHO2G12 (1),
CPMV2G12HL (2),
HT2G12HL (3),
CPMV2G12HEL (4), and
HT2G12HEL (5). A sample of size markers (visible on the Coomassie-
stained gel but not the blots) was loaded between lanes 1 and 2.
doi:10.1371/journal.pone.0013976.g002
Figure 3. Relative abundances of glycoforms for each of the purified 2G12 variants with diagrammatic structures of each
glycotype. Data was generated by mass-spectrometric analysis of the two predicted tryptic peptides representing the same glycosylation site
(EEQYN
297STYR and TKPREEQYN
297STYR). N-glycan structure abbreviations are given according to http://www.proglycan.com.
doi:10.1371/journal.pone.0013976.g003
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CHO-produced material. The observed differences can only
partially be explained by the presence of H chain degradation
products (Figure 2) because the gp120/protein-L ratios are also
slightly reduced. The reduction in this ratio is somewhat more
prominent for CPMV-HT-produced 2G12 and may indicate
incomplete or improper assembly of the antibody that could be
due to the disruption of host cell processes by the high-level over-
expression of a foreign protein. However, it may also be related to
the extraction and purification of different batches of antibody, for
which there is inherent variation in any production system.
HIV-1 neutralisation by
CPMV2G12 and
HT2G12
The ability of the purified IgG molecules to neutralise HIV was
determined via a syncytium inhibition assay using a T cell line-
adapted HIV-1 isolate, HIV-1 RF (Table 3). In each case the
amount of antibody provided was determined by SPR using a
protein-A surface. The results show that all the preparations of
purified 2G12, whether produced by delRNA-2 + RNA-1 or
CPMV-HT, neutralise HIV in vitro with the IC50 measurements
similar to that obtained using CHO-produced 2G12.
Discussion
The work reported in this manuscript describes an extensive
characterisation of a purified full-length IgG produced transiently
Figure 4. Ratios of the binding rate signals obtained by SPR on the purified 2G12 variants. Values were derived using protein-A, protein-
L, and gp120 surfaces represented by linear regressions. (A) protein-L/protein-A ratio. (B) gp120/protein-A ratio. (C) gp120/protein-L ratio.
doi:10.1371/journal.pone.0013976.g004
Table 2. Response Ratios determined for
CPMV2G12 and
HT2G12 variants relative to
CHO2G12.
2G12 variant
Protein-L/
Protein-A
gp120/
Protein-A
gp120/
Protein-L
CPMV2G12HL 98.82 88.80 89.84
HT2G12HL 101.97 78.19 76.62
CPMV2G12HEL 81.09 69.61 85.84
HT2G12HEL 92.44 68.96 74.46
doi:10.1371/journal.pone.0013976.t002
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systems. This builds on our previous studies [25,26] showing that
full-length antibodies can be successfully expressed to high levels
using such systems. The results show that 2G12 expressed using
both systems can be purified in substantial quantities, and retains
the ability to bind HIV gp120 and to neutralise HIV infections in
vitro at levels similar to the CHO-produced standard antibody.
Therefore, by comparison to previous studies that have used
transgenic plants to produce 2G12, we show that the potential
impact of transient high-level expression systems on plant host cell
processes, has a negligible effect on recombinant antibody
characteristics.
There have been several previous reports of the successful
production of full-size antibodies in plants using both replicating
and non-replicating transient expression systems. Using two
replicating TMV constructs separately expressing the H and L
chains of mAb CO17-1A, Verch et al. [30] were able to
demonstrate the assembly of full-length antibodies in N. benthami-
ana but did not provide any information as to their yield or
properties. Using a non-replicating, non-viral system, Vaquero et
al. [31] transiently expressed mAb T84.66 specific for the human
carcinoembryonic antigen in N. tabacum and achieved a yield of
approximately 1 mg purified T84.66 per kg of fresh weight leaf
material but no characterisation of the plant-expressed antibody
was reported. Giritch et al. [32] and Huang et al. [33] showed that
it is possible to produce high-levels of a full-length antibody in N.
Benthamiana, using non-competing viral vectors based on TMV and
PVX, or a single DNA virus-based replicon, respectively. Both
studies demonstrated antigen binding and reported the purifica-
tion of the antibody, but did not give final yields of the purification
or conduct a detailed analysis of the product. Activity, in the form
of neutralisation assays, was demonstrated for the chimaeric mAb
cPIPP, which reached expression levels of 20 mg/kg fresh weight
leaf tissue in N. tabacum from non-viral transient expression [34].
This chimaeric antibody was later characterised in terms of its
glycosylation profile [28]. More recently, Vezina et al. [35] and
Villani et al [36] reported the transient expression of antibodies
C5-1 and H10, respectively, also without replication, in N.
benthamiana. In both instances, the purified antibodies were
analysed with respect to their glycosylation status and, in the case
of H10, the antibody was also subjected to immunohistochemical
analysis.
The maximum level of purified 2G12 (105 mg/kg fresh weight
tissue) was obtained when the CPMV-HT system was used for
expression and the antibody was retained in the ER through the
incorporation of a KDEL sequence on the H chain. This level is
approximately one-third the maximum previously reported as
accumulating in infiltrated tissue (325 mg/Kg)[26] when separate
constructs are used to express the H and L chains. There are
probably two main factors responsible for this reduction: the losses
occurring during the purification process, which were 15 to 30%
depending on the expression strategy (Table 1), and the nature of
the large scale infiltrations. The latter were carried out by hand
using syringe-infiltration which is relatively inefficient on a large-
scale. Therefore, not all of the tissue included in the extraction
process was actually infiltrated, including the mid-vein, which
contributes a significant fraction to the weight of the harvested
tissue. However, despite this the levels of purified antibodies were
similar to that reported by Villani et al. [36] which used vacuum
infiltration to deliver Agrobacterium suspensions to N. benthamiana
tissue. It the absence of ER retention, the yield of antibody
dropped by about 50%, consistent with previous observations [26].
When delRNA-2 constructs were used to express 2G12 in the
presence of RNA-1, the yields of purified IgG were approximately
5-fold less than when the corresponding constructs were expressed
from CPMV-HT, which is also consistent with our previous
observations and is due to differences in the 59UTR of CPMV
RNA-2 [26].
Glycosylation is an essential post-translational modification for
glycoprotein maturation and, in the case of antibodies, may affect
activity, immunogenicity, and other secondary functions [37,38].
Since CPMV RNA-1 is known to induce a proliferation of ER-
derived membranes [11], it is possible that this could affect the
glycosylation of 2G12 produced using the delRNA-2 system.
Likewise, the high levels of antibody produced using CPMV-HT
might affect glycosylation patterns by overloading the glycosyla-
tion machinery. Glycan analysis of the purified 2G12 molecules
showed that the pattern of glycosylation depended exclusively on
whether the molecule was ER-retained, with no significant
differences being found between the delRNA-2 + RNA-1 and
the CPMV-HT-expressed material. When the 2G12 was retained
within the ER, high-mannose forms predominated while in the
absence of retention, typical plant-specific glycans were found.
Overall, the glycosylation pattern is similar to that found for 2G12
expressed in plant cell culture [27] and in transgenic tobacco
plants (Sack M and Stadlmann J, unpublished observations).
These observations indicate that neither the membrane prolifer-
ation caused by RNA-1, nor the high levels of protein produced in
response to CPMV-HT affect the post-translational modification
of the IgG.
A syncytium inhibition assay demonstrated that 2G12 produced
by delRNA-2 + RNA-1 was capable of neutralising HIV in vitro at
doses very similar to that found with CHO-produced 2G12,
irrespective of whether the antibody was ER-retained. The non-
ER-retained 2G12 produced from CPMV-HT appeared to have a
slightly inferior neutralising activity than that of CHO-produced
2G12 while that of the ER-retained version appeared to be worse
still. Nonetheless, all the plant-expressed 2G12 preparations
described here are still very effective at neutralising HIV and, in
fact, their IC50s are within the range of IC50s reported for CHO-
produced 2G12[21,39]. Importantly, the values are also similar to
those of 2G12 produced in transgenic transgenic corn [21,22] and
tobacco (unpublished observations).
When the purified antibodies were subjected to comparison
with
CHO2G12 in an in vitro binding assay, binding response ratios
determined by SPR showed that the plant-derived purified
antibodies were slightly less active than their CHO-derived
counterpart. This can mostly be attributed to the presence of
degradation products. The quality of the 2G12 preparations is also
slightly lower than that observed for 2G12 derived from transgenic
Table 3. Virus neutralisation by
CPMV2G12 and
HT2G12 variants, and
CHO2G12.
2G12 variant
CHO2G12
CPMV2G12HL
HT2G12HL
CPMV2G12HEL
HT2G12HEL
IC50 (mg/ml) 3.72 3.13 4.42 3.41 6.81
doi:10.1371/journal.pone.0013976.t003
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reduction in ligand binding activity observed using the highly
accurate and precise assay in this study is not critical for initial
biopharmaceutical product development, including biophysical
and biochemical characterization and biopotency assays. Howev-
er, it does suggest that quality issues deserve particular attention in
the development of transient expression systems for the production
of biopharmaceuticals. The discrepancy in 2G12 quality mea-
surements between stable transgenic and transient expression in
plants may be due in part to the physiological state of the leaf
material used. Antibody degradation in planta can be a function of
growth conditions and leaf age [40] and may also be influenced by
the defense-related physiological adjustment by the plant that
accompanies agro-infiltration [41], which may well include
changes to proteolytic activity [42]. Furthermore, in the present
study, the co-infiltration approach could result in variable
expression levels for H chain and L chain in individual cells
thereby resulting in free chains rather than assembled IgG. To
address this, it will be possible to use a new generation of minimal
binary vectors designed for use with CPMV-HT that allow both
chains to be expressed together [43]. Alternatively, a DNA virus
replicon system based on Bean yellow dwarf virus (BeYDV)[44] is also
able to direct the transient expression both H and L chains from a
single vector [33]. Nevertheless, considering that a one-step
purification method was used here, the antigen binding abilities of
the preparations are reasonable compared with
CHO2G12, which
has undergone extra purification steps during its production
according to clinically validated procedures.
Another property of RNA virus-directed replication that may
compromise protein quality is the relatively low fidelity of RNA-
dependent RNA polymerases (RdRp). RNA viruses are well
known to accumulate mutations at a very high rate [45], which on
one hand, allows them to quickly adapt to variations in
environmental pressures [46,47], but on the other hand, renders
them susceptible to a very subtle decrease in RdRp fidelity, which
can force a virus into error catastrophe [48,49]. Consequently, for
the use of virus vectors for the expression of therapeutics, there is
concern over the accumulation of mutations during the multiple
rounds of replication, and therefore the quality of the expressed
proteins. The error rate per replication cycle of a number of RNA
viruses have been reported to be in the range of approximately
1610
23 to 1610
25 mutations per base [48,50,51]. This suggests
that a heterologous insert of 1 kb in a virus genome of 10 kb, will
on average contain 0.01 to 1 mutations per replication cycle
depending on the virus vector used. Cell to cell movement would
then initiate a compounding replication cycle on any mutated
genome. Furthermore, as there is no selection pressure against
mutations in a heterologous insert, genetic drift is likely to occur.
Given that some mutations will be synonymous and that the host
cell possesses protein quality control mechanisms, it is currently
very speculative to suggest that this will have a significant impact
on the quality of a pharmaceutical protein produced by viral
vectors. However, more detailed future studies will be required to
demonstrate that replicating systems are robust and reliable
enough to reproducibly deliver pharmaceuticals satisfying regula-
tory requirements. These concerns do not, of course, apply to
systems such as CPMV-HT, which do not rely on RNA
replication.
The results presented here demonstrate that it is possible to use
transient expression systems based on CPMV to achieve the rapid,
highlevel productionof a high-quality therapeutic antibody.To our
knowledge, this is the most detailed characterisation of transiently
produced antibody from plants and the first to consider the effects of
a virus vector on the quality of recombinant proteins from plants.
The results show that in terms of HIV neutralisation, 2G12
produced by replicating and non-replicating CPMV expression
systems are comparable to the CHO-produced antibody and 2G12
produced in transgenic plants. Furthermore, we believe that
remaining quality issues can be resolved by further optimizing up-
and downstream processing. The results might be taken as a first
indication that the relatively high error rate of RdRp may be
acceptable for the production of protein pharmaceuticals, although
much more work is required to rigorously test this hypothesis. In
conclusion, given the speed and ease with which large quantities of
the recombinant antibody were produced, the transient expression
systems detailed in this study are of great use for the research and
development of pharmaceutical proteins whether ultimately pro-
duced in this manner or not.
Materials and Methods
Plasmids and agroinfiltration
The binary vector constructs used in this study have been
previously described [26]. Briefly, sequences corresponding to the
heavy and light chains of 2G12 were inserted into the cloning
vector pM81-FSC1 using the appropriate restriction sites. This
vector contains the CPMV RNA-2 sequence, from which the
entire coding region may be replaced, flanked by a 35S promoter
and nos terminator [52]. For expression with the wt RNA-2 leader
(delRNA-2), PacI/AscI fragments containing the entire expression
cassette were transferred into similarly digested pBINPLUS [53] to
give pBD2G12H, pBD2G12HE and pBD2G12L (Figure 1). For
expression with the CPMV-HT leader, DraIII/AscI fragments
containing the gene of interest, the 39UTR, and the nos terminator
were transferred into a similarly digested pBINPLUS construct
carrying the HT mutation [26] to give pBD2G12H-HT,
pBD2G12HE-HT and pBD2G12L-HT (Figure 1).
Expression plasmids were maintained in Agrobacteria tumefaciens
strain LBA4404. Stationary phase liquid cultures grown in LB
containing 50 mg/ml Kanamycin, 50 mg/ml Streptomycin, and
50 mg/ml Rifampicin were pelleted and resuspended to OD600 of
1.0 in MMA: 10 mM MES (2-[N-morpholino]ethanesulfonic acid;
Sigma-Aldrich) pH 5.6, 10 mM MgCl2, 100 mM Acetosyringone
(Sigma-Aldrich). Cultures harbouring binary plasmids for the
expression of each antibody chain, RNA-1 and/or P19 were
mixed at equal parts and pressure infiltrated into the underside of
N. benthamiana leaves using a needleless syringe. Agroinfiltration
was performed on all of the fully expanded leaves of 6 week-old
plants grown in glasshouses maintained at 23–25uC with a
16 hour photoperiod.
Antibody extraction and purification
Infiltrated leaves were homogenized in a Waring blender with 3
volumes of PBS (pH 6.0, 5 mM EDTA, 0.05% Triton X-100).
After centrifugation (15 minutes at 8000 g) the supernatant was
subjected to a pH shift to 8.5, resulting in formation of a
precipitate. After a second centrifugation (30 minutes at 8000 g)
the supernatant was passed through a paper filter and antibody
was purified by Protein-A chromatography as previously described
[54] with the exception that 100 mM glycine pH 3.6 with
100 mM fructose was used to elute from the Protein-A column.
Eluates were immediately buffered with 1 M acetate buffer
pH 4.75 and extensively dialysed against 10 mM acetate buffer
pH 4.75 containing 1 mM ETDA. This buffer is similar to the
buffer used for CHO-derived antibody (10 mM sodium acetate
pH 4.5–5.0, 10% Maltose) and has been used for plant-derived
2G12 in previous studies (Ramessar et al., 2008). It has been found
to be suitable for prolonged storage at 4uC without significant loss
High-Yield Plant mAb Quality
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dialysed samples was determined by SPR and, if necessary,
ultrafiltration (30 kDa MWCO) was used to concentrate the
antibody.
SDS-PAGE and Western blotting
2G12 preparations were separated by SDS-PAGE under
reducing conditions [55] and either stained with Coomassie blue
for direct visualisation or electroblotted onto nitrocellulose.
Membranes were probed with either a goat anti-human IgG (Fc
specific) conjugated to horseradish peroxidase (Sigma-Aldrich) or a
goat anti-human IgG (Fab specific) conjugated to horseradish
peroxidase (Sigma-Aldrich). Antigenic bands were visualized by
electrochemiluminescence (ECL) captured on Hyperfilm (Amer-
sham Biosciences).
Surface Plasmon Resonance (SPR) spectroscopy
Antibody quantification, quality assessment, and antigen
binding assays were carried out using a BIACORE 2000
instrument (Biacore, GE Healthcare) at 25uC using HBS-EP
(10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.05% Tween
20, pH 7.4) as the running buffer. Recombinant Protein-A (Sigma-
Aldrich, 200 mg/ml in 10 mM sodium acetate, pH 4.2), Protein-L
(Sigma-Aldrich, 62.5 mg/ml in 10 mM sodium acetate, pH 4.5)
and gp120 HIV-1BaL gp120, NIH AIDS Research and Reference
Reagent Program, www.aidsreagent.org, 22.2 mg/ml in 10 mM
sodium acetate pH 4.75) were immobilised to a CM5-rg
sensorchip by EDC/NHS coupling and an activated/deactivated
surface was used as a reference for blank subtraction. The contact
times for activation and deactivation were increased to 10 min,
and for coupling to 15 min to achieve high immobilization levels.
Approximately 8.7 k Response Units (RU) of protein-A, 7.3 kRU
protein-L, and 16.6 kRU of gp120 were immobilized, resulting in
high binding capacity and high mass-transport limitation for all
surfaces. Samples were diluted such that binding signals were in
the linear range and dilution series were injected over all four cells
simultaneously. Regeneration was achieved with 0.5 M citrate
pH 3.0 for gp120 and 30 mM HCl for protein-A and protein-L,
and surfaces were stable for several hundred cycles.
The response ratios were determined by linear regression of the
endpoint signals recorded for several antibody concentrations after
plotting the gp120 response against the protein-A and protein-L
response, and the protein-L response against the protein-A
response. The relative antigen-binding activity was derived by
dividing the slopes by the corresponding slopes obtained for the
CHO2G12 reference (Polymun Scientific GmbH, Vienna, Austria).
Data evaluation was performed using BIAevaluation v4.1 and
Microcal Origin v8.0.
Glycosylation analysis
Glycosylation analysis was carried out on the appropriate protein
bands (either HC or full-size IgG) excised from a coomassie-stained
SDS-PAGE gel. Destaining, carbamidomethylation, trypsin digest
and extraction from gel pieces was performed as previously
described [56]. Fractionation of the peptides by capillary reverse
phase chromatography was also performed as described [56].
Comparison of MS data from the tryptic peptides was compared to
tryptic digests of 2G12 performed in silico using the PeptideMass
program (http://www.expasy.org/tools/peptide-mass.html). Tryp-
tic glycopeptide datasets were generated by the addition of glycan
mass increments to the masses of the two identified peptides.
HIV neutralisation assay
HIV-1 neutralisation was assessed using a syncytium inhibition
assay as previously described [14,57]. Ten two-fold serial dilutions
(start concentration: 100 mg/ml) of
CHO2G12,
CPMV2G12HL,
CPMV2G12HEL,
HT2G12HL, and
HT2G12HEL, and a non-
neutralising control were pre-incubated with HIV-1 RF at 10
2–10
3
TCID50/ml for 1 hr at 37uC. CD4-positive human AA-2 cells
were added at a density of 4610
5 cells/ml and incubated for a
further 5 days. Experiments were performed with eight replicates
per antibody dilution step. The presence of at least one syncytium
per well was scored as positive for infection. The 50% inhibiting
concentrations (IC50) were calculated according to the method of
Reed and Muench [58] using the concentrations present during
the antibody-virus pre-incubation step.
Supporting Information
Figure S1 Effects of the presence of RNA-1 on the accumulation
and glysosylation of 2G12 expressed by the delRNA-2 system. (A)
Measurements of 2G12 accumulation made by SPR using a
protein-A surface on crude plant extracts expressing secreted (HL)
or ER retained (HEL) 2G12 in the presence or absence of RNA-1.
Values represent the average of three replicates 6 SE and is
representative of 2 individual experiments. (B) Relative abundanc-
es of glycoforms of delRNA-2-produced 2G12 variants extracted 6
or 12 days after agro-infiltration and isolated from total soluble
protein by 10% SDS-PAGE. H = heavy chain, L = light chain,
HE = heavy chain with KDEL. N-glycan structure abbreviations
are given according to http://www.proglycan.com.
Found at: doi:10.1371/journal.pone.0013976.s001 (9.12 MB TIF)
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